HCM, NT-proBNP and HCM Risk Evaluation; Arrhythmic Burden in Cardiac Amyloidosis Obesity and Heart Failure; Postural Orthostatic Tachycardia Syndrome (POTS)

In this week's View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). He then examines the ten-year follow-up of the PARTNER 2A trial and compares the transcatheter aortic valve replacement (TAVR) outcomes to results from the Partner 2 SAPIEN XT and SAPIEN 3 studies. He follows this with a report on how clopidogrel may offer a long-term edge over aspirin after percutaneous coronary intervention (PCI). Finally, Dr. Eagle summarizes HELIUS cohort findings demonstrating that LDL-C, Lp(a), and hsCRP provide complementary, independent insights for identifying long-term atherosclerotic cardiovascular disease (ASCVD) risk across diverse ethnic populations.   Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. He also highlights low rates of hypertension and hyperlipidemia treatment among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, and summarizes evidence that resistance training, particularly when combined with aerobic exercise, is associated with a lower risk of cardiovascular (CV) disease, especially myocardial infarction, in women. Finally, he discusses the CAMERA-MRI II study in patients with atrial fibrillation and left ventricular systolic dysfunction (LVSD), where catheter ablation significantly improved left ventricular ejection fraction (LVEF) regardless of late gadolinium enhancement status.  Subscribe to Eagle's Eye View 

In this week's View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. He reviews the SOGALDI-PEF trial, where patients with low plasma renin levels experienced greater blood pressure reduction with spironolactone/dapagliflozin compared to dapagliflozin alone. Next, he discusses the FAVOR III trial, which found that QFR-guided percutaneous coronary intervention improved five-year outcomes versus angiography guidance, with most benefits occurring in the first two years. Lastly, Dr. Eagle examines two renal disease studies addressing optimal chronic kidney disease (CKD) GFR thresholds and the benefits of finerenone in CKD patients. 

In this week's View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involving a single intravenous infusion—Verve-2—which targets PCSK9 expression in the liver and may represent a promising future strategy for treating familial hyperlipidemia. Finally, Dr. Eagle discusses recent findings on antihypertensive drug combinations, emphasizing those regimens that provide optimal efficacy while minimizing adverse effects that often lead to early treatment discontinuation. 

In this week's View, Dr. Eagle looks at recent research found in ACC's new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining 'low risk' chest pain and its evaluation in the emergency departments. Next, a discussion of how negative patient outcomes were associated with late pericardial effusion post-left atrial appendage occlusion (LAAO) device implantation. Finally, Dr. Eagle summarizes the ALLEVIATE-HF trial that explored heart failure (HF) risk detection with an insertable cardiac monitor paired with a centrally coordinated nurse-led diuretic intervention.  Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection fraction (HFpEF) and functional mitral regurgitation (MR). Finally, Dr. Eagle summarizes a new study on the use of digitoxin and digoxin in patients with heart failure.  Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment. He then examines the EXCALIBUR study, which aims to better characterize arrhythmic burden in patients with cardiac amyloidosis. Next, he discusses research identifying obesity as a significant risk factor for heart failure, highlighting key findings and clinical implications. Finally, he summarizes new evidence on the use of ivabradine and propranolol in treating postural orthostatic tachycardia syndrome (POTS).    Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. He then explores evidence showing that blood pressure reduction can deliver comparable cardiovascular benefits for patients with chronic kidney disease (CKD). Another study reviewed in this episode assesses the outcomes of continuing versus switching direct oral anticoagulant (DOAC) therapy in patients with atrial fibrillation (AFib) who experience breakthrough stroke. Finally, Dr. Eagle summarizes the AVANTE-GUARD trial, which evaluates pulsed field ablation as a first-line treatment for patients with persistent AFib.   Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle looks at the NOBLE trial evaluating whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is best for patients with unprotected left main coronary artery disease (CAD). He then explores a report highlighting nanosecond pulsed field ablation (nsPFA) and its safety and efficacy at one year for paroxysmal atrial fibrillation. Finally, Dr. Eagle presents a summary of the TRIDENT trial, which compares a triple‑pill antihypertensive strategy with conventional therapy and finds a positive impact on hypertension management and stroke risk following intracerebral hemorrhage.  Subscribe to Eagle's Eye View       

In this week's View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life. He then explores current evidence and strategies to address sex hormone-associated thrombotic and cardiovascular risk. Next, Dr. Eagle examines the OCEANIC-STROKE trial which studied asundexian and its potential to lower recurrent stroke risk in patients with noncardioembolic stroke or transient ischemic attack. Finally, Dr. Eagle asks the question, is high cardiorespiratory fitness associated with longer lifespan and lower multimorbidity?  Subscribe to Eagle's Eye View